Company intelligence / Profile preview

Prime Synthesis

Petaluma, California, United States

Ownership: Private
Development stage: Other

Overview

Prime Synthesis, Inc. was founded in 1988, specializing in the development and manufacturing of controlled pore glass (CPG) solid supports essential for DNA/RNA synthesis. It served as a critical supplier to the pharma, biopharma, research, and diagnostics markets. The company was acquired by LGC in 2016 and now operates as part of LGC's Biosearch Technologies portfolio.

Modalities: Synthetic oligonucleotideSmall molecule (for resin intermediates)
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Prime Synthesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prime Synthesis.

Explore the full profile